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Abstract 
Microscopy and medical imaging are related in their exploitation of electromagnetic waves, but 
were developed to satisfy differing needs, namely to observe small objects or to look inside 
subjects/objects, respectively. Together, these techniques can help elucidate complex biological 
processes and better understand health and disease. A current major challenge is to delineate 
mechanisms governing cell migration and tissue invasion in organismal development, the immune 
system and in human diseases such as cancer where the spatiotemporal tracking of small cell 
numbers in live animal models is extremely challenging. 
Multi-modal multi-scale in vivo cell tracking integrates medical and optical imaging. Fuelled by 
basic research in cancer biology and cell-based therapeutics, it has been enabled by technological 
advances providing enhanced resolution, sensitivity and multiplexing capabilities. Here, we review 
which imaging modalities have been successfully used for in vivo cell tracking and how this 
challenging task has benefitted from combining macroscopic with microscopic techniques.  
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Introduction 
Two major discoveries, one enabling observation of smaller objects and the other allowing to look 
inside subjects/objects, significantly boosted biological/biomedical research. The first compound 
microscope was invented by Hans and Zaccharias Jansen in the late 16th century, which triggered 
later microscopy development that in turn enabled the direct observation of atoms, single 
molecules and single-/multi-cellular organisms including their dynamics. The second 
transformation was Wilhelm Roentgen’s discovery of X-rays in 1895, which enabled investigations 
of inner subject/object structures in a non-invasive way (genetic effects of radiation were only 
recognized later) and founded medical imaging. Both microscopy and medical imaging rely on the 
interaction of biological matter with electromagnetic waves, but medical imaging employs a wider 
range than microscopy including α/β/γ-ray-emitting radioisotopes, X-rays, visible (VIS)/near-
infrared (NIR) light, radio waves and ultrasound (Fig.1). Medical imaging revolutionized the 
diagnosis and treatment of human disease by providing anatomical, physiological and molecular 
information (Mankoff, 2007). Imaging modalities differ in their capabilities and limitations (Fig.1), 
hence combination technologies were introduced to exploit them best (‘multi-modal imaging’). For 
example, positron emission tomography (PET) offers best-in-class sensitivity and absolute 
quantification but only at millimetre resolution and was combined with modalities providing higher 
resolution such as computed tomography (CT) (Basu et al., 2014) or magnetic resonance imaging 
(MRI) (Catana, 2017). How medical imaging can be used to develop biomarkers providing 
diagnostic, prognostic, predictive, and treatment monitoring information was recently standardized 
(O'Connor et al., 2017). Photoacoustic tomography (PAT) and Cerenkov luminescence imaging 
(CLI) are special in that they both rely on electromagnetic waves from different parts of the 
spectrum for imaging. PAT delivers NIR laser pulses into biological tissues with the latter absorbing 
and converting some of the laser pulse energy into heat, leading to transient thermoelastic 
expansion and thus wideband ultrasonic emission (Ntziachristos et al., 2005;Wang and Yao, 
2016). CLI relies on the collection of light produced by charged particles traversing through 
biological tissue with a velocity greater than the phase velocity of light in that medium (Ciarrocchi 
and Belcari, 2017). Brightfield microscopy and, less frequently, fluorescence microscopy are 
routine techniques providing confirmatory pathology information obtained from biopsied tissues. 
Recently, automated multiplex fluorescence histopathology (Mansfield et al., 2008;Stack et al., 
2014) has enabled rigorous tissue profiling, e.g. immune infiltration in tumour tissues (Galon et al., 
2014).  
Here, we review which imaging modalities have been successfully used for in vivo cell tracking 
and how this challenging task benefitted from combining macroscopic with microscopic techniques. 
For detailed information on the instrumentation of individual imaging technologies and their use, we 
provide references to recent specialist literature. 
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The need for in vivo cell tracking in cancer research 
A major challenge in cancer research is to better understand the mechanisms governing cell 
migration and tissue invasion. A plethora of different models including animal tumour models are 
used for this purpose. It remains extremely challenging to reliably quantify the in vivo distribution, 
relocalisation, and viability of cancer cells in animal tumour models, which are sufficiently large to 
be optically opaque. For example, the spatiotemporal quantification of cancer cell spread in mouse 
models of metastasis is a needle-in-a-haystack task. Traditionally, in preclinical cancer research 
one target organ of metastasis was chosen, large animal cohorts were sacrificed at different time 
points to overcome inter-animal variability and these approaches were paired with microscopic or 
flow cytometric analyses in target tissues as read-outs. Whole-body imaging can (i) inform on in 
vivo cell distribution, for example, visualize unexpected metastatic sites; (ii) provide quantitative 
data, e.g. live tumour volumes/metastatic burden and extent of cell therapy on-site residence over 
time; (iii) provide cell viability data; (iv) reduce inter-subject variability as serial imaging of the same 
subjects provides statistically better paired data; and (v) can minimize animal usage during 
preclinical development. Similarly, when developing anti-cancer drugs, it is important to establish 
targeting efficiency, pharmacokinetics and pharmacodynamics, whether there is spatial 
heterogeneity to the delivery, and if drug presence is related to therapeutic efficacy. Again, this can 
be achieved by combining preclinical whole-body cancer cell tracking with conventional molecular 
imaging of drugs, for example, by image-based quantification of the extent a labelled drug reaches 
in vivo traceable cancer cells and whether the drug is delivered to all primary/secondary lesions. 
Another area where in vivo cell tracking is an emerging valuable tool is the development and 
clinical translation of cell-based therapies. Unlike conventional chemotherapeutics or targeted 
therapies, they cannot be considered as ‘fire-and-forget’ weapons in the battle against cancer as 
they are live cell products, but little is known about their in vivo distribution and fate both 
preclinically and clinically. In 2017, the FDA approved the first clinical products, tisagenlecleucel 
and axicabtagene ciloleucel, which are autologous CD19b-targeted chimeric antigen receptor T-
cell (CAR-T) immunotherapies for the treatment of certain blood cancers (B-cell lymphomas; 
(USFood&DrugAdministration, 2017a;b)). CAR-T immunotherapies have the potential to be 
curative, but not all patients respond and sometimes the effects are only temporary (Maude et al., 
2018;Neelapu et al., 2017;Schuster et al., 2017). CAR-T are also associated with severe/life-
threatening side-effects and fatalities during trials (Linette et al., 2013;Saudemont et al., 2018). 
Moreover, cellular immunotherapeutics for treating solid tumours are at the clinical trial stages but 
not yet routinely available to patients. Traditional approaches in preclinical cell therapy 
development rely on dose escalation with toxicity evaluation, tumorigenicity tests, and qPCR-based 
persistence determination. However, clinical trials are still performed without knowledge about the 
in vivo distribution and fate of the administered therapeutic cells, making it impossible to 
adequately monitor and assess their safety. Major unresolved questions in cell therapy 
 © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
development and use both preclinically and clinically are: (i) the whole-body distribution of 
therapeutic cells; (ii) their potential for re-location during treatment and the kinetics of this process; 
(iii) whether on-target off-site toxicities occur; (iv) how long the administered cells survive; and (v) 
which biomarkers are best suited to predict and monitor cell therapy efficacy. Whole-body imaging-
based in vivo cell tracking can inform on many of these aspects in a truly non-invasive manner. 
 
Rendering cells traceable in vivo 
In vivo cell tracking exploits molecular imaging mechanisms but differs from conventional 
molecular imaging as contrast agents or contrast-forming features are added to the cells before 
their administration into subjects. On some occasions, features that can be exploited for generating 
contrast are intrinsic, for example, when cancer cells express molecules that show low or no 
expression in other tissues. Under these circumstances conventional molecular imaging offers 
tracking possibilities both preclinically and clinically (e.g. sodium iodide symporter (NIS) in thyroid 
metastases (Kogai and Brent, 2012;Portulano et al., 2014), glutamate carboxypeptidase 2 (PSMA) 
in prostate cancer (Oliveira et al., 2017;Perera et al., 2016), carcinoembryonic antigen in colorectal 
cancer (Tiernan et al., 2013), or melanin in melanomas (Tsao et al., 2012)). However, in most 
cases contrast agents or contrast-forming features must be introduced to the cells of interest, and, 
crucially, this must be done with the experimental design in mind (technology, tracking time, 
tracking interval, preclinical/clinical setting).  
Labels can be introduced into cells via two fundamentally different methodologies. So-called 
‘direct cell labelling’ employs ready-to-use contrast agents (e.g. organic fluorophores, quantum 
dots, iron oxide nanoparticles, F-19-fluorinated contrast agents, chelated radiometals etc.), which 
are introduced into cells either due to the contrast agents being cell permeant, or through assisted 
uptake (e.g. by transfection or internalisation) (Kircher et al., 2011). The alternative is ‘indirect cell 
labelling’, whereby a genetically encoded reporter is ectopically introduced to the cells mostly by 
viral transduction to ensure genomic integration and long-term expression. In some cases, 
episomal plasmids (e.g. delivered using transfection or electroporation to deliver the DNA) can also 
be useful. Lately, gene editing approaches have been reported for reporter insertion, which are 
have advantages over viral transduction as they offer precise control over the genomic site of 
reporter insertion (Bressan et al., 2017). Contrast formation relies on either (a) label uptake by 
reporters that are transporters, (b) label binding to cell surface-expressed reporters, or (c) 
expression of contrast-forming proteins (e.g. fluorescent proteins, luciferases). All these indirect 
mechanisms find utility in reporter gene applications, which are used to image intracellular 
molecular events or, as discussed here, to perform in vivo cell tracking.  
Reporter genes (Tab.1) have critical advantages over direct labelling for cell tracking. First, the 
observation period is independent of the contrast agent, for example, not affected by the half-lives 
of a radioisotope. Second, genetic encoding avoids label dilution phenomena, which are 
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particularly limiting observation times in the case of fast growing cells (e.g. cancer cells or 
expanding T cells). Third, genetic encoding circumvents complex cell labelling procedures and 
potential associated cell damage/toxicities. A drawback of the indirect cell labelling approach is that 
it requires genetic engineering. However, this is neither a concern for preclinical experimentation 
nor for cell therapies already reliant on it (e.g. CAR-T) (Saudemont, Jespers, 2018). A caveat 
exists in the potential for immune system activity against reporters as cells expressing foreign 
reporters can be detected, attacked, and cleared by an intact immune system. This may best be 
overcome by using host reporter proteins that are normally endogenously expressed in the 
organism of interest. Importantly, these host reporters should be endogenously expressed in only a 
limited number of host tissues, to exclude interference with the experimental goals, and ideally at 
low levels to ensure favourable contrast. 
 
Optical imaging – versatility and limitations 
Selecting technology for the task of in vivo cell tracking is not a straightforward task. The group of 
optical imaging technologies overall offers the widest versatility across multiple length scales, 
spanning microscopy and macroscopic medical imaging (Fig.1). Fluorescence is the only imaging 
modality capable to bridge the length scales (macroscopic, (sub)cellular, molecular), hence would 
appear most attractive for the task of in vivo cell tracking. For example, using one fluorescent dye, 
whole-body imaging and tissue microscopy data were acquired (Swirski et al., 2007). However, no 
single optical approach can cover all requirements for in vivo cell tracking despite recent 
technological advancements. For example, improvements in fluorescence microscopy have 
allowed deeper sample penetration and imaging larger specimen (cf. light sheet and expansion 
microscopy, tissue clearing (Ariel, 2017;Karagiannis and Boyden, 2018;Whitehead et al., 2017)). 
Moreover, intravital fluorescence microscopy offers cellular resolution in live animals, but only in 
very limited fields of view and in certain accessible tissues (Alieva et al., 2014;Condeelis and 
Segall, 2003;Entenberg et al., 2017;Entenberg et al., 2018;Pittet and Weissleder, 2011). In 
contrast, both fluorescence and bioluminescence whole-body imaging (BLI and FRI/FLI) offer large 
fields of views but suffer from poor resolution (Fig.1) that is insufficient for in vivo cell tracking and 
are planar imaging technologies and thus unable to provide 3D or quantitative data. BLI offers 
orders of magnitude better sensitivities than all macroscopic fluorescence techniques and is 
inexpensive but requires the tissue availability of a luminescence substrate, is limited in its 
multiplexing capability, and confined to preclinical use (Dunlap, 2014;Jiang et al., 2016;Li et al., 
2013). To obtain true 3D data a tomographic design is required. This is provided by optical 
projection tomography (OPT), which can be considered to be the optical analogue of X-ray 
computed tomography (CT). OPT operates on the micrometre to millimetre scales (Cheddad et al., 
2012;Sharpe et al., 2002) thereby bridging the scale gap between BLI/FLI and microscopy. It can 
either provide tomographic data on light absorption or fluorescence signals, and has been used in 
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live zebrafish (Bassi et al., 2011;McGinty et al., 2011), fruit flies (Arranz et al., 2014;Vinegoni et al., 
2008) and for whole organ imaging in mice (Alanentalo et al., 2008;Gleave et al., 2012;Gupta et 
al., 2013). An alternative approach offering larger fields of view in the centimetre range is diffuse 
optical tomography or fluorescence mediated tomography (FMT), which exploits photon tissue 
propagation theory to allow for 3D reconstruction at centimetre depth but its resolution is hampered 
by weak signals and high scattering (Fig.1; (Graves et al., 2004;Lian et al., 2017;Ntziachristos, 
2006;Venugopal et al., 2010;Wang et al., 2015;Zacharakis et al., 2011)). The group of 
photoacoustic techniques including PAT (Dean-Ben et al., 2017;Valluru et al., 2016;Wang and 
Yao, 2016) and its more refined variants multispectral optoacoustic tomography (MSOT; (Ma et al., 
2009;Ntziachristos and Razansky, 2010)) and raster scanning optoacoustic mesoscopy (RSOM; 
(Omar et al., 2015)) are the newest additions to the optical imaging portfolio. They are special in 
that light is only used for excitation while sound is what is recorded, thereby rendering them less 
affected by the shortcomings of using light for imaging thick samples. However, it is important to 
realize that fundamentally all optical whole-body imaging techniques are severely affected by 
differential light absorption, scatter and poor depth penetration, precluding full 3D quantification 
(Fig.1). Hence, they play a minor role in medical imaging, albeit with a few notable exceptions 
although outside the field of cell tracking. First, optical coherence tomography (OCT) in 
ophthalmology (Jung et al., 2011;Tao et al., 2013) and dermatology (Mogensen et al., 2009;Olsen 
et al., 2015), and, second, photoacoustic imaging as a promising emerging tool in oncology and for 
the assessment of Crohn’s disease (Diot et al., 2017;Knieling et al., 2017;McNally et al., 
2016;Valluru, Wilson, 2016). In summary, despite the combined imaging opportunities provided by 
the various optical approaches, currently, there is no suitable route for reliable in vivo cell tracking 
available, which requires high sensitivity at good resolution within large fields of view while also 
providing anatomical context.  
 
Multi-modal imaging is necessary for in vivo cell tracking 
For successful in vivo cell tracking, it is necessary to build on the strengths of different imaging 
modalities and combine them with microscopy. CT and MRI both offer anatomical reference, 
whereby MRI excels in soft-tissue contrast and avoids the use of ionising radiation but is more 
expensive. The exquisite sensitivity of BLI has been frequently exploited in combination with MRI, 
e.g. for imaging tumour growth or treatment response in preclinical models (Jost et al., 
2009;McCann et al., 2009). In animal models, cell tracking by MRI using, for example, iron oxide 
nanoparticles has been reported, but cross-correlation studies with luciferase/BLI have 
demonstrated its shortcomings in sensitivity (Song et al., 2009;Zhang et al., 2011). Dual-contrast 
agents for 19F-MRI and fluorescence, e.g. perfluorocarbon-TexasRed, have been used to track 
tumour-associated macrophages in mice (Makela and Foster, 2018). MRI reporter genes have also 
been developed (Tab.1) and have the advantage of co-registration with soft-tissue anatomy and 
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certain functional imaging parameters. However, MRI sensitivity remains poor compared to BLI 
and radionuclide imaging (Fig.1). While fluorescent proteins and luciferases are excellent 
reporters, which also offer multiplexing capability (Mezzanotte et al., 2017;Rodriguez et al., 2017), 
they suffer from the limitations of optical imaging (see above). In contrast, radionuclide imaging 
(PET, SPECT) offers best depth penetration and absolute quantification (Lajtos et al., 2014) with 
preclinical resolutions ≤1 mm (Deleye et al., 2013;Nagy et al., 2013), but radionuclide imaging is 
more complex to perform and cell detection sensitivities are highly reporter-dependent and cell-
specific. Cellular detection sensitivities have been reported to be as good as hundreds/thousands 
for cancer cells using NIS together with its PET and SPECT radiotracers, respectively, (Diocou et 
al., 2017;Fruhwirth et al., 2014) and tens of thousands for smaller T-cells using various different 
reporters in preclinical experiments (Moroz et al., 2015). As PET-CT/MRI and SPECT-CT/MRI 
instruments are nowadays preclinical and clinical standard, these multimodal approaches offer 
high sensitivities via PET or SPECT combined with CT or MRI, which add anatomical reference at 
higher resolution than radionuclide imaging techniques (Fig.1). CLI is unlikely to play a role in in 
vivo cell tracking as it is less sensitive as compared to PET/SPECT and suffering from the 
shortcomings of optical imaging at depth (see above). Importantly, fluorescence is an excellent 
partner to complement radionuclide imaging as it excels in the microscopic domain enabling spatial 
identification of fluorescent cells in tissues (ex vivo in tissues or in vivo if combined with intravital 
imaging of specific regions of interest). An additional practical aspect is that genetically encoded 
fluorescent reporters can be used as selection markers during generation and characterization of 
radionuclide/fluorescence dual-mode reporter-expressing cells.  
 
Multi-scale in vivo cell tracking in practice 
Multi-modal multi-scale imaging has enabled quantitative in vivo tracking of tumour growth and 
spontaneous metastasis in preclinical models. SPECT/CT and PET/CT were used to determine 
location, organ selectivity and extent of metastasis, while fluorescence streamlined cell line 
generation and characterization, guided dissection, and enabled straightforward fluorescence 
histology (Fig.2) (Diocou, Volpe, 2017;Fruhwirth, Diocou, 2014;Hekman et al., 2017;Minn et al., 
2005;Ray et al., 2004;Volpe et al., 2018). Various radionuclide reporters have been used including 
those offering options to kill administered cells (e.g. HSV1-tk (Kokoris and Black, 2002;Ponomarev 
et al., 2004), deoxycytidine kinases (dCK) (Lee et al., 2017;Likar et al., 2010)). Another reporter, 
NIS, has a long history (Carlson et al., 2009;Che et al., 2005;Dingli et al., 2006;Groot-Wassink et 
al., 2004;Higuchi et al., 2009;Merron et al., 2007;Sieger et al., 2003;Terrovitis et al., 2008) and 
excels in cell tracking because it accurately reports cell viability as transport relies on an intact 
Na+/K+-gradient (Dohan et al., 2003;Portulano, Paroder-Belenitsky, 2014). The NIS-fluorescent 
protein fusion reporter (NIS-FP) (Fruhwirth, Diocou, 2014;Volpe, Man, 2018) offers direct 
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accessibility of its subcellular localization (a prerequisite for NIS tracer transport/imaging) at all 
experimental stages and aids histological tissue segmentation.  
This approach also enabled imaging how drugs affect tumour progression/metastasis in animal 
models. For example, etoposide was found to not abrogate spontaneous metastasis in a preclinical 
model of breast cancer. Metabolic molecular imaging using [18F]FDG-PET showed etoposide 
efficacy in cancer tissues due to etoposide-mediated glucose transporter down-modulation (Witney 
et al., 2009). But it was NIS-FP that, unaffected by etoposide, enabled quantification of tumour 
progression in different microenvironments (using serial dual-isotope PET/SPECT/CT imaging). 
NIS-FP also significantly streamlined the ex vivo analysis of etoposide effects on reporter 
expressing cancer cells (Fruhwirth, Diocou, 2014). Other preclinical radionuclide-fluorescence 
studies employed, for example, dCK/GFP to investigate tumour growth and T-cell trafficking (Likar, 
Zurita, 2010), or used SPECT-traceable neural stem cells for glioma targeting (Cheng et al., 2016).  
Multiplex imaging also enabled differential tracking of molecular and cellular therapeutics to 
cancer tissues in animal models. In luciferase-expressing non-small cell lung cancers gadolinium- 
and Cy5.5-labelled nanoparticles were evaluated as potential orotracheally administered tumour 
diagnostics. Tumour cell tracking relied on BLI while MRI visualized the diagnostic agent and 
provided anatomical reference, and fluorescence streamlined histological confirmation (Bianchi et 
al., 2014). Combined serial PET/SPECT/CT-fluorescence imaging also enabled tracking of 
radiolabelled liposomal mevalonate pathway inhibitors to NIS-FP-expressing tumours and 
metastases (Fig.3). This study demonstrated the need for a longer interval between administration 
of this γδ T-cell therapy booster (Lavoue et al., 2012;Mattarollo et al., 2007;Parente-Pereira et al., 
2014) and the corresponding γδ T-cell therapy (Edmonds et al., 2016). Conventional reporter 
gene-based tracking of adoptive cell therapies has also been performed (Koya et al., 2010;Likar, 
Zurita, 2010;Moroz, Zhang, 2015). The full potential of co-tracking the cell therapy to the tumour 
was unlocked only very recently; by co-tracking PET-traceable γδ T-cells to NIS-FP-traceable 
cancer cells in an animal model of human breast cancer, demonstrating that liposomal alendronate 
pre-treatment caused higher tumour uptake of γδ T-cells (Man et al., 2017). Notably, also as a 
proof-of-principle study in human glioma patients has recently been performed, employing PET for 
intra-organ administered CAR-T tracking with MRI providing anatomical context (Keu, Witney, 
2017). 
 
Conclusion and outlook 
Multi-modal multi-scale in vivo cell tracking is a rapidly growing interdisciplinary area, which has 
been fuelled by the rise of cell-based therapies and enabled by recent technological advances 
providing enhanced resolution, sensitivity and multiplexing capabilities on both the macroscopic 
and microscopic scales. For long-term in vivo cancer cell tracking, reporter gene methodologies 
are particularly attractive. The most promising methodologies to-date exploit the exquisite 
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sensitivity, multiplex capability and 3D quantification of radionuclide imaging and combine them 
with fluorescence methodologies, thereby allowing convenient cell line generation and reliable and 
versatile ex vivo microscopic analyses. In vivo cell tracking cannot always be directly translated for 
human use because fluorescent proteins, luciferases and certain non-human radionuclide 
reporters have no direct clinical utility. But importantly, preclinical in vivo cell tracking serves as a 
versatile platform for understanding the underlying biology and to validate therapeutic concepts, 
thereby informing subsequent clinical trials. However, in the case of live cell therapies, in vivo cell 
tracking provides the means for long-term monitoring in patients if required. It is noteworthy that 
cell therapies are emerging also in other fields than cancer including transplantation immunology 
(Boardman et al., 2017) and regenerative medicine (Ellison et al., 2013;Rashid et al., 2015). Multi-
modal multi-scale in vivo imaging-afforded cell tracking is therefore likely to become increasingly 
important for the successful development of such cell therapies, particularly in the context of 
therapy safety and monitoring.  
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Figure 1. Macroscopic and microscopic imaging modalities | Imaging modalities are ordered 
according to the electromagnetic spectrum they exploit for imaging (top: high energy; bottom: low 
energy). Routinely achievable spatial resolution (left end) and fields of view (right end) are shown 
in red. Where bars are blue they overlap red bars and indicate the same parameters but 
achievable with instruments used routinely in the clinic. Imaging depth is shown in green alongside 
sensitivity ranges. Instrument cost estimations are classified as ($) <125,000 $, ($$) 125-300,000 $ 
and ($$$) >300,000 $. * Fluorophore detection can suffer from photobleaching by excitation light. 
** Generated by positron annihilation (511keV). *** Contrast agents sometimes used to obtain 
different anatomical/functional information. **** In ‘emission mode’ comparable to other 
fluorescence modalities (~nM). ***** Highly dependent on contrast agent. & Multichannel MRI 
imaging has been shown to be feasible (Zabow et al., 2008). 
 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/
 © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
 
Figure 2. Dual-mode radionuclide-fluorescence metastasis tracking is quantitative and 
provides data across multiple length scales | Representative results of metastasis tracking in a 
murine model of inflammatory breast cancer using the radionuclide-fluorescence fusion reporter 
NIS-GFP are shown. NIS served as an in vivo reporter and was imaged by PET/CT using the NIS 
tracer [18F]BF4-. (A/left) On day 19 post tumour inoculation, the primary tumour (yellow dashed 
line) was clearly identified but no metastasis. It is noteworthy that endogenous NIS signals (white 
descriptors) were also recorded, i.e. the thyroid and salivary glands (Th+SG), the stomach (S), 
and, at very low levels, some parts of the mammary and lachrymal glands. Neither of these 
endogenous signals interfered with sites of expected metastasis in this tumour model. The bladder 
(B) signal stems from tracer excretion. (A/right) On day 29 post tumour inoculation, metastases 
were clearly identified in the lung (yellow dotted line; numbered individual metastases) and in some 
lymph nodes (inguinal (ILN), axillary (AxLN); yellow arrowheads). The primary tumour (yellow 
dashed line) had also invaded into the peritoneal wall. Images presented are maximum intensity 
projections (MIP). (B) A 3D implementation of the Otsu thresholding technique enabled 3D surface 
rendering of cancerous tissues; these are superimposed onto a PET MIP. Lung metastases are 
shown in white, metastatic axillary lymph nodes in red, the metastatic inguinal lymph node in 
yellow, and the primary tumour that invaded into the peritoneal wall in turquoise. (C) Radiotracer 
uptake into cancerous tissues was quantified from 3D images (%injected dose (ID)) and 
normalized by the corresponding volumes (%ID/mL). Individual lung metastases correspond to the 
numbers in (A). (D) NIS-GFP’s fluorescence properties guided animal dissection. As exemplars 
brightfield and fluorescence images of the lung with several metastatic lesions and two positive 
lymph nodes are shown. (E) Immunofluorescence histology of the primary tumour. NIS-GFP 
expressing cancer cells were directly identified without the need for antibody staining. Blood 
vessels were stained with a rabbit antibody against mouse PECAM-1/CD31 and for nuclei (DAPI) 
before being imaged by confocal fluorescence microscopy. Data demonstrated vascularization 
heterogeneity of the primary tumour. The image also shows that the NIS-GFP reporter 
predominantly resides in the plasma membranes of the tumour cells demonstrating its correct 
localization to be functional in vivo and enabling tumour cell segmentation.  
[The figure is reproduced with permission and minor rearrangements from (Volpe, Man, 2018)].  
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Figure 3. Tracking a nanomedicine to primary and secondary cancer lesions | Liposomal 
alendronate was radiolabelled with the PET isotope 89Zr (89Zr-PLA) and administered to animals 
bearing primary breast tumours that had already spontaneously metastasized (as determined by 
99mTcO4- -afforded NIS-SPECT/CT). (A) Coronal and sagittal SPECT-CT (top; cancer cells) and 
PET-CT (bottom; nanomedicine) images centred at the tumours of the same animal are shown at 
indicated time points after intravenous administration of 89Zr-PLA. SPECT-CT images show 
identical biodistribution over time with high uptake in endogenous NIS-expressing organs 
(stomach, thyroid) and NIS-FP-expressing cancer cells in the primary tumour (T) and metastases 
(LNmet and Lumet). PET-CT images show the increasing uptake of 89Zr-PLA over time in the primary 
tumour (T), spleen (Sp), liver (L), and bone (B) and decreasing amounts in the blood pool/heart 
(H). For corresponding time–activity curves refer to (Edmonds, Volpe, 2016). (B) Co-registered 
SPECT/PET/CT images of the primary tumour (from left to right: sagittal, coronal, transverse) 
showing a high degree of colocalization but also intra-tumoral heterogeneity of 89Zr-PLA (purple 
scale); 99mTcO4- -NIS signals (green scale) show live cancer cells. (C) Autoradiography images 
(left, 99mTc; right, 89Zr) of a coronal slice from the same tumour as in (B) showing a high degree of 
colocalization and heterogeneity. (D) Fluorescence microscopy of an adjacent slice of the same 
tumour as in (B/C) showing areas of high and low microvascular density (determined by anti-CD31 
staining).  
[The figure is reproduced from (Edmonds, Volpe, 2016) 
(https://pubs.acs.org/doi/10.1021/acsnano.6b05935) with permission from ACS; further 
permissions related to the material excerpted should be directed to the ACS]. 
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Tab.1 Reporter genes and corresponding imaging tracers and substrates. 
Reporter 
type 
Reporter 
name 
Imaging tracer / substrate Properties Limitations Ref. 
Cell surface 
receptor 
Human 
somato-
statin 
receptor 
type 2 
(hSSTr2) 
PET: 68Ga-DOTATOC, 68Ga-DOTATATE; 
SPECT: 111In-DOTA-BASS;  
(best tracers selected here). 
G-protein-coupled 
receptor; several 
tracers cross the BBB. 
Endogenous expression in brain, 
adrenal glands, kidneys, spleen, 
stomach and many tumours (i.e. 
SCLC, pituitary, endocrine, pancreatic, 
paraganglioma, medullary thyroid 
carcinoma, pheochromocytoma); 
tracers may cause cell signalling and 
change proliferation. 
(Chaudhuri et al., 
2001;Rogers et al., 
1999;Rogers et al., 
2000;Zinn et al., 2000) 
 
Cell surface 
receptor 
Dopamin 
receptor 
(D2R)- 
PET: [18F]FESP, [11C]Raclopride, [11C]N-
methylspiperone. 
G-protein-coupled 
receptor; tracers cross 
BBB.  
Slow clearance of [18F]FESP; high 
background in the pituitary gland and 
striatum due to endogenous 
expression.  
(Hwang et al., 2007;Liang 
et al., 2001;MacLaren et 
al., 1999;Satyamurthy et 
al., 1990) 
Cell surface 
receptor 
Transferrin 
receptor 
(TfR) 
MRI: Transferrin-conjugated SPIO.  Transferrin-conjugated SPIO particles 
are internalized by cells ectopically 
expressing TfR. 
(Weissleder et al., 2000) 
Cell surface-
expressed 
antigen 
Human 
Carcinoemb
ryonic 
antigen 
(hCEA)* 
PET: 124I-anti-CEA scFv-Fc H310A antibody 
fragment, [18F]FB-T84.66 diabody; 
SPECT: 99mTc-anti-CEA Fab’ (FDA approved), 
111In-ZCE-025, 111In-anti-CEA F023C5i. 
Overexpressed in 
pancreatic, gastric, 
colorectal and 
medullary thyroid 
cancers. 
CEA not expressed in healthy adult 
human cells, except for colon lumen; 
tracers do not cross BBB.  
(Griffin et al., 
1991;Hammarstrom, 
1999;Hong et al., 
2008;Kenanova et al., 
2009) 
Cell surface 
protein 
Glutamate 
carboxypept
idase 2* 
(PSMA) 
PET: [18F]DCFPyL, [18F]DCFBC; 
SPECT: [125I]DCFPyL; 
anti-PSMA antibodies can be flexibly labelled, 
e.g J951-IR800. 
 Background signal in kidneys; tracers 
do not cross BBB. 
(Castanares et al., 2014) 
Transporter Sodium 
iodide sym-
porter (NIS) 
[human, 
mouse, rat] 
PET: 124I-, [18F]BF4-, [18F]SO3F-, [18F]PF6-; 
SPECT: 99mTcO4-; 123I-. 
Symports sodium ions. Endogenously expressed in l\thyroid, 
stomach, lacrimal, salivary and 
lactating mammary glands, small 
intestine, choroid plexus and testicles; 
tracers do not cross BBB. 
(Dai et al., 1996;Jauregui-
Osoro et al., 2010;Jiang 
et al., 2018;Khoshnevisan 
et al., 2017;Khoshnevisan 
et al., 2016) 
Transporter Norepineph
rin transpo-
rter (NET) 
PET: [124I]MIBG; [11C]hydroxyephedrine; 
SPECT: [123I]MIBG. 
 Endogenously expressed in organs 
with sympathetic innervation (heart, 
brain), tracers do not cross BBB. 
(Moroz et al., 2007) 
Transporter Dopamin 
transporter 
(DAT) 
PET: [11C]CFT, [11C]PE2I, [18F]FP-CIT; 
SPECT: 123I-β-CIT, 123I-FP-CIT, 123I-Ioflupane, 
99mTRODAT. 
NaCl-dependent; 
tracers cross BBB. 
Few data in public domain.  Patent: (Martin Pulé 
(London), 2015) 
Artificial cell 
surface 
Anti-PEG 
Fab 
PET: 124I-PEG-SHPP; 
MRI: SPIO-PEG; 
Some tracers cross 
BBB; PEG is non-toxic 
Iodine tracers bear risk of deiodination. (Chuang et al., 2010) 
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molecule fragment* Fluorescence: e.g. NIR797-PEG. and FDA approved. 
Artificial 
protein 
Lysine-rich 
protein 
MRI: Chemical exchange saturation transfer 
(CEST). 
Frequency-selective 
contrast. 
 (Farrar et al., 2015;Gilad 
et al., 2007) 
Enzyme HSV1-tk 
and 
mutants- 
PET: [124I]FIAU, [18F]FEAU, [18F]FHBG. 
 
Kinase causing cellular 
tracer trapping; suicide 
gene property. 
Tracers do not cross the BBB; high 
activity in organs involved in clearance.  
(Tjuvajev et al., 1995) 
Enzyme hmtk2/hΔT
K2 
PET: [124I]FIAU, [18F]FEAU, [18F]FMAU (hTK2-
N93D/L109F). 
Kinase causing cellular 
tracer trapping. 
Tracers do not cross the BBB. (Ponomarev et al., 2007) 
Enzyme hdCK PET: [124I]FIAU, [18F]FEAU.  Kinase causing cellular 
tracer trapping. 
Tracers do not cross the BBB.  (Lee, Zhang, 2017;Likar, 
Zurita, 2010) 
Enzyme β-galacto-
sidase 
PET: 2-(4-[123I]iodophenyl)ethyl-1-thio-β-D-
galactopyranoside, 3-(2’-[18F]fluoroethoxy)-2-
nitrophenyl-β-D-galactopyranoside, 3-
[11C]methoxy-2-nitrophenyl-β-D-
galactopyranoside; SPECT: 5-[125I]iodoindol-3-
yl-β-D-galactopyranoside; PAT: 4-chloro-3-
bromoindole-galactose (X-gal); MRI: EgadMe. 
Glycoside hydrolase. Cellular toxicity may change with 
substrates. 
(Li et al., 2007;Liu and 
Mason, 2010;Louie et al., 
2000) 
Enzyme Tyrosinase PET: [18F]P3BZA-melanin avid probe; 
MRI: Melanin due to ability to chelate metal 
ions (Fe3+); PAT: Melanin. 
Copper-containing 
enzyme. 
Low expression levels; no clinical use. (Krumholz et al., 
2011;Ponomarev, 
Doubrovin, 
2004;Weissleder et al., 
1997) 
Enzyme Firefly 
luciferase 
Luciferin and derivatives. Substrate-dependent, 
(often: orange/red) 
No clinical use. (Mezzanotte, van 't Root, 
2017;Ugarova, 1989) 
Enzyme Renilla 
luciferase 
Coelenterazine 482-547 nm emission No clinical use. (Lorenz et al., 1991) 
Enzyme Gaussia 
luciferase 
Coelenterazine 480-600 nm emission No clinical use. (Inoue et al., 
2011;Tannous, 
2009;Tannous et al., 
2005) 
Enzyme Green Click 
Beetle 
luciferase 
Luciferin, naphtyl luciferin. Emission varies in 
sub-species: green 
(548 nm), yellow-green 
(565 nm), orange (594 
nm) and near-infrared. 
No clinical use. (Biggley et al., 
1967;Mezzanotte et al., 
2014;Mezzanotte et al., 
2011;Wood et al., 1989) 
Monomeric 
fluorescent 
proteins 
(mFP) 
eGFP 
A206K** 
 488(ex)/507(em) nm No clinical use. (Ormo et al., 1996) 
 mCherry**  587/610 nm No clinical use. (Shaner et al., 2004) 
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* Any other modality can be used provided a suitable contrast forming moiety will be attached to PEG and the CEA antibodies, respectively. 
**Can be used in fusion with other reporter genes without introduction of artificial protein clustering. 
 
 
 TagRFP**  555/584 nm No clinical use. (Merzlyak et al., 2007) 
 mPlum**  590/649 nm; also used 
for PAT. 
No clinical use. (Lin et al., 2009) 
 mNeptune**  600/650 nm No clinical use. (Kremers et al., 2009) 
Fluorescent 
protein 
E2-Crimson  611/646 nm No clinical use, tetramer. (Liu et al., 2013) 
NIR 
fluorescent 
proteins 
IFP1.4 Exogenously added biliverdin (BV) 684/708 nm No clinical use; dimer; need for 
exogenous BV. 
(Shcherbakova and 
Verkhusha, 2013;Shu et 
al., 2009) 
 iRFP 670 Endogenous biliverdin sufficient 643/670 nm; also used 
for PAT. 
No clinical use; dimer. (Deliolanis et al., 
2014;Filonov et al., 
2011;Shcherbakova and 
Verkhusha, 2013) 
 iRFP 713 Endogenous biliverdin sufficient 690/713 nm; also used 
for PAT. 
No clinical use; dimer. (Deliolanis, Ale, 
2014;Filonov, Piatkevich, 
2011;Shcherbakova and 
Verkhusha, 2013) 
Photoactivat
able protein 
Kaede**  518/580 nm No clinical use. (Ando et al., 2002) 
IrisFP**  516/580 nm No clinical use. (Adam et al., 2008) 
Photoconver
tible protein 
Dendra2**  507 nm to 573 nm 
switch 
No clinical use; switch is irreversible. (Gurskaya et al., 2006) 
Iron carrier 
protein 
Ferritin MRI: iron.  Iron is not equally distributed across 
the brain and therefore may cause 
local susceptibility shifts that are above 
the MRI detection limit. 
(Cohen et al., 
2005;Genove et al., 2005) 
Gas-filled 
protein 
complex 
GvpA/ 
GvpC 
Ultrasound: gas vesicles generate contrast. Reporter gene cluster 
required. 
Not yet validated for use in mammalian 
cells. 
(Raymond W. Bourdeau, 
2018) 
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